Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials)

By sjmartinez • June 27, 2023

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F; ENHANCE investigators. Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials). Am J Respir Crit Care Med. 2023 Jun 26. doi: 10.1164/rccm.202306-0944OC. Epub ahead of print. PMID: 37364283.

Tags: COPD, ensifentrine, nebulized, PDE3 and PDE4 inhibitor, Publications, Pulmonary, Critical Care & Sleep Medicine

cfDNA derived gene signatures as surrogate for microvascular invasion in HCC

Gong R, Wang L, Xue D, Cai J, Jiang Y, Huang J, Zhu J, Li Z, Ke A, Shi G, Wang J, Wang W, Zheng[...]

Hidradenitis in Pediatrics

Dhillon S, Horneck N, Smogorzewski J. Hidradenitis in Pediatrics. Adv Pediatr. 2026 Aug;73(1):295-307. doi: 10.1016/j.yapd.2025.12.007. Epub 2026 May 21. PMID: 42481098.

Impact of antenatal screening for Chlamydia and Gonorrhea on pregnancy outcomes in South African women

Nyemba DC, de Voux A, Mvududu R, Peters RPH, Delany-Moretlwe S, Johnson LF, Coates TJ, Myer L, Davey DLJ. Impact of antenatal screening for Chlamydia[...]